Schroder Investment Management Group Has $6.40 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Schroder Investment Management Group raised its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 415.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 407,215 shares of the company's stock after purchasing an additional 328,204 shares during the period. Schroder Investment Management Group's holdings in Dr. Reddy's Laboratories were worth $6,397,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. boosted its stake in shares of Dr. Reddy's Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after buying an additional 9,373,412 shares during the period. Aikya Investment Management Ltd increased its position in shares of Dr. Reddy's Laboratories by 416.1% in the fourth quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after purchasing an additional 4,523,303 shares during the period. Vanguard Group Inc. raised its stake in Dr. Reddy's Laboratories by 397.2% in the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after purchasing an additional 3,911,404 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Dr. Reddy's Laboratories by 462.1% during the fourth quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock worth $44,444,000 after purchasing an additional 2,313,987 shares during the period. Finally, Fisher Asset Management LLC grew its stake in Dr. Reddy's Laboratories by 402.5% during the fourth quarter. Fisher Asset Management LLC now owns 2,468,722 shares of the company's stock worth $38,981,000 after buying an additional 1,977,419 shares in the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Price Performance

NYSE:RDY traded up $0.60 during trading hours on Wednesday, hitting $13.03. The company's stock had a trading volume of 4,320,297 shares, compared to its average volume of 1,383,842. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a market capitalization of $10.88 billion, a P/E ratio of 20.75 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a twelve month low of $12.26 and a twelve month high of $16.89. The stock has a fifty day simple moving average of $13.23 and a 200-day simple moving average of $14.41.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Nomura downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.